Status:
RECRUITING
Real World Study of End-stage Liver Disease in China
Lead Sponsor:
Huashan Hospital
Conditions:
End Stage Liver DIsease
Complication
Eligibility:
All Genders
18-75 years
Brief Summary
The aims of this study are exploring the current situation of end-stage liver disease in China, and the optimization of diagnosis and treatment. Liver cirrhosis often accompanied by a series of compli...
Detailed Description
The aims of this study are exploring the current situation of end-stage liver disease in China, and the optimization of diagnosis and treatment. Liver cirrhosis includes cirrhosis caused by hepatitis,...
Eligibility Criteria
Inclusion
- Informed consent of patients.
- Diagnosis of any of the following diseases: acute decompensation of cirrhosis, chronic and acute liver failure, chronic liver failure and hepatocellular carcinoma (stage III-IV)
Exclusion
- HIV antibody positive and AIDS patients
- Serious psychiatric history, especially depression. Severe mental illness is defined as major depression or psychosis, suicide attempts, hospitalization due to mental illness or a period of disability due to mental illness.
- Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs.
- Patients with other malignant tumors (excluding those cured).
- Pregnant, lactating women or women of childbearing age who are ready to conceive.
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2029
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT04037995
Start Date
September 1 2019
End Date
September 1 2029
Last Update
July 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HuaShan Hospital
Shanghai, Shanghai Municipality, China, 200040